Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Double-dummy, Randomized, Crossover Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) During Initial Dose Escalation in Healthy Volunteers

NCT00702676 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00702676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00702676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Double-dummy, Randomized, Crossover Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) During Initial Dose Escalation in Healthy Volunteers
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2008
Completion date
August 31, 2008
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers